Thera-SAbDab

BENUFUTAMAB

> Structural Summary

Therapeutic	Benufutamab
Target	TNFRSF10B
Heavy Chain	EVQLQQSGAEVVKPGASVKLSCKASGFNIKDTFIHWVKQAPGQGLEWIGRIDPANTNTKYDPKFQGKATITTDTSSNTAYMELSSLRSEDTAVYYCVRGLYTYYFDYWGQGTLVTVSS
Light Chain	EIVMTQSPATLSVSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIKFASQSITGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQGNSWPYTFGQGTKLEIK
100% seqID Fv Structure	6t3j [Fvs: AB, FG]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	6t3j [Fvs: AB, FG]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Phase-I/II
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2019
INN Year Recommended	2020
Companies Involved	Genmab, VU University Medical Center, iDD Biotech
Conditions Approved	na
Conditions Active	Solid tumours, Multiple myeloma
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]